... evaluate the activity of an association of 1G3-Cu with 5 cytotoxic agents used in chemotherapy having different modes of action. Data show no additive effect with camptothecin and cisplatin, additivity with paclitaxel and MG132, and synergy with doxorubicin. Results suggest that the multivalent Cu...

... of doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 (AC) administered intravenously on day 1 every 3 weeks were followed by 12 courses of weekly paclitaxel 80 mg/m 2 , prior to radiation therapy and surgery. Although the method of premedication was left to the judgment of each investigator, administration...

... combination of doxorubicin and paclitaxel (AT) for 3 cycles. Methods: Chemo-naïve women with breast cancer receiving doxorubicin (60 mg/m 2 ) and paclitaxel (200 mg/m 2 ) were eligible. Patients received palonosetron 0.25 mg intravenously before chemotherapy, however, all patients also received...

... chemotherapeutic resistance. This study investigates the molecular responses of ER+ breast cancer cell lines to the chemotherapeutic agent, doxorubicin, in the presence or absence of estrogen. Methods: ER+ MCF-7 and T47-D cells were cultured in hormone-starved or estrogen-containing media with or without...

...Kyu-Hyoung Lim; Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang Objective: The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC...

... XIAP expression in U87MG glioblastoma using stable shRNA, and cells were treated with taxol, BCNU, temozolomide, cisplatin, etoposide, resveratrol (Rsv), vincristine and doxorubicin. We analyzed cell viability, cell cycle, apoptosis and senescence. Results: XIAP KD cells were more sensitive...

...G. Roubaud; M. Gross-Goupil; H. Wallerand; H. de Clermont; M.S. Dilhuydy; A. Ravaud Background/Aims: Metastatic renal cell carcinoma (mRCC) can be rapidly progressive when tumors exhibit sarcomatoid or Fuhrman grade 4 features. Efficacy of gemcitabine (Gem) with doxorubicin (Dox) in sarcomatoid...

... potentially curative resections for gastric cancer. Methods: After surgery, patients were randomly assigned to the EAP or control arm. Chemotherapy included 3 courses, administered every 28 days. Each cycle consisted of doxorubicin (20 mg/m 2 ) on days 1 and 7, cisplatin (40 mg/m 2 ) on days 2 and 8...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Cardiotoxicity Ejection fraction, left ventricular Doxorubicin Peak...

... with cyclophosphamide and doxorubicin in patients with metastatic breast cancer. Of 62 evaluable patients, 31 received UFT® (350 mg/m 2 /day orally x 14 days), doxorubicin (50 mg/m 2 intravenously [IV] day 1) and cyclophosphamide (500 mg/m 2 IV day 1). The other 31 patients received 5-FU (500 mg/m 2 IV days 1 and 8...

...Tsukasa Hotta; Hiroshi Tanimura; Hiroki Yamaue; Makoto Iwahashi; Masaji Tani; Takuya Tsunoda; Mikiko Tamai; Kohei Noguchi; Shizuma Mizobata; Kazuo Arii; Hiroshi Terasawa Resistance to doxorubicin (DOX) is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance (MDR) gene...

...Nissim Haim; Medy Tsalik; Eliezer Robinson The results of two schedules of the combination of etoposide, doxorubicin, and cisplatin (EAP) in gastric cancer are reported. EAP-1 was administered as originally reported and consisted of i.v. doxorubicin (adriamycin) 20 mg/m 2 on days 1 and 7, i.v...

... neutropenia, may necessitate dose reductions and may ultimately limit its use as a long-term treatment. Sequential or simultaneous administration of Taxol and doxorubicin may enhance response rates. There appears to be no complete cross-resistance between the two drugs. Current trials are exploring the best...

... to either methotrexate (10 -6 -10 -4 M ), doxorubicin (10 -7 -10 -5 M ) or mitoxantrone (10 -7 -10 -5 M). In HPMC exposed to doxorubicin (10 -6 M ) the intracellular transport of potassium, as assessed with 86 Rb as its analogue, was not affected. Methotrexate (10 -5 M ) diminished Na, K-ATPase activity...

..., adenosine and guanosine triphosphate levels, and 14 C-amino acid incorporation, of rat hearts treated with doxorubicin and some of its derivatives, recent products of pharmacological research aimed at selecting less toxic antiblastic agents. In rats treated in vivo, we further examined the ultrastructural...

...Narayana S. Kamath; Manik P. Chitnis The efficacy of dipyrone to modulate antitumor activity of mitoxantrone (MTN) and doxorubicin (DOX) was studied in vivo in mice bearing P388 murine lymphocytic leukemia sensitive (P388/S) and resistant (P388/DOX) to DOX. P388/DOX-bearing mice demonstrated...

...Giuseppe Giaccone; Michela Donadio; Gianmaria Bonardi; Franco Testore; Alessandro Calciati Nineteen evaluable patients with advanced breast cancer were treated with a combination of doxorubicin and etoposide. Patients had measurable disease, received only mild pretreatment and most had good general...

...Andrea Martoni; Edera Piana; Monica Guaraldi; Giuseppina Cilenti; Antonio Farris; Ferruccio Saccani; Giorgio Becchi; Franco Pannuti The aim of the present study is to confirm the antitumor activity of orally administered idarubicin (IDA) in patients with advanced breast cancer. Doxorubicin (ADRIA...

... stages III and IV Chemotherapy Cyclophosphamide Doxorubicin Adriamycin Cisplatin Laparotomy, second-look Second-effort surgery Oncology 1991 ;48:7 12 « 1991 S. Karger AG. Basel 0030 2414 91 «4SI 0007 S 2.75 0 Chemotherapy (CAP) for the Treatment of Advanced Ovarian Cancer and Second-Effort...

... derivatives or coenzyme Q 10 could provide protection against doxorubicin-related cardiac damage. Rat heart slices were incubated for 60 min in a Warburg apparatus at 38°C with 4 mM L-carnitine or 1 m M propionyl carnitine or 15 μM coenzyme Q 10 to which 25 μM doxorubicin was added. Cellular oxygen uptake...